Clinical Trials Logo

Filter by:
NCT ID: NCT05707884 Recruiting - Clinical trials for Sedation Set-up Time

Volatiles in Critical Care After Free Flap Surgery

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Patients undergoing complex free flap surgery are randomised to volatile or intravenous sedation in terms of subsequent intensive care sedation, based on the in-hospital standard of care. For study purposes, differences in management (set-up times, change of filters, etc.) will be investigated in relation to accelerated awakening and possibly improved neurocognition after the end of sedation.

NCT ID: NCT05708612 Recruiting - Fecal Incontinence Clinical Trials

Safety and Performance of a Silicone Implant for Fecal Incontinence Treatment (SimplyFI)

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The purpose of the clinical investigation is to verify that the device under investigation (SimplyFI) is appropriate to significantly improve fecal incontinence in patients in whom its use is indicated.

NCT ID: NCT05711524 Recruiting - Bleeding Clinical Trials

Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding

Start date: April 1, 2023
Phase: Phase 4
Study type: Interventional

The goal of this quality improvement study is to compare pathogen-reduced cryoprecipitate with traditional cryoprecipitate in liver transplant and cardiovascular patients. The investigators hypothesize that by having immediate access to a readily available thawed blood product that replaces fibrinogen (the main substrate of a blood clot), early bleeding can be treated before it escalates into uncontrolled hemorrhage, and therefore additional blood products, like platelets, plasma and red blood cells can be avoided. Participants will be given one of the two FDA-approved blood products.

NCT ID: NCT05712733 Recruiting - Clinical trials for Antibiotic Resistant Infection

Cholecystitis From a Microbiological and Histopathological Perspective

Start date: April 1, 2023
Phase:
Study type: Observational [Patient Registry]

The aim of this project is to investigate the presence of bacteria in the gallbladder wall and the bile in patients undergoing cholecystectomy, to determine if the standard empirical antibiotic treatment used currently is effective against the most common pathogens.

NCT ID: NCT05713734 Recruiting - Bleeding Disorder Clinical Trials

Bleeding of Unknown Cause: a Swiss Case-control Study

SWISS-BUC
Start date: April 1, 2023
Phase:
Study type: Observational

The goal of this prospective cohort is to identified specific biological patterns in patients with a bleeding of unknown cause and to study the specific mechanisms of the bleeding disorder for each subset of patients.

NCT ID: NCT05714670 Recruiting - Lupus Nephritis Clinical Trials

The Effect of Curcumin on the Clinical Outcome of Pediatric Patients With Active Lupus Nephritis

Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

Pediatric Lupus nephritis which is a sever and common complication to childhood onset systemic lupus erythematous is an aggressive inflammatory process triggered by the deposition of antigen-antibody complex in kidney tissue. The complex stimulates production of multiple immune cells, activating Inflammasome NLRP3 that plays massive role in stimulating various cytokines like IL-6. The inflammation also causes elevation in proteinuria and serum creatinine levels beside other inflammatory markers elevation (CRP )and (ESR). These children are treated with a standard regimen consists of an immunomodulator (mycophenolate mofetil) with strong steroid anti-inflammatory and also hydroxychloroquine is added to the regimen to decrease the intensity of the flares and management of arthritis symptoms. In our study we are introducing a powerful antioxidant and anti-inflammatory drug with nephroprotective benefits which is curcumin capsules. The drug showed success in managing different autoimmune and inflammatory diseases as rheumatoid arthritis and Crohn's disease, it also showed dramatic improvement in lupus nephritis models in previous experimental study. The study primary outcome is will be the composite of the effect of curcumin on Urine protein-to-creatinine ratio and NLPR3 Inflammasome levels in blood. Patients meeting the study inclusion criteria will be educated firmly about the disease details and all information about the drug, then will be randomly assigned to one of two groups, the first group receiving the standard therapy only while the second one receiving the standard therapy beside the curcumin 1000 mg capsules orally daily, a third small group of healthy children as a control for normal inflammasome levels. Patients in the first two groups will undergo baseline evaluation at the beginning of the study including Patients' demographic data, anthropometric measures and medication history. Moreover, collecting patients' medical history which includes Duration of systemic lupus, Duration of lupus nephritis, other organs involvement, past and current medical condition or prescribed and OTC medications. Laboratory Evaluation and renal function assessment will include Inflammasome levels in blood using ELISA technique using Human NLRP3 ELISA Kit, Serum creatinine levels, Protein in urine levels, estimated glomerular filtration rate (eGFR) using Original Schwartz Equations, Inflammatory biomarkers (ESR, CRP), anti-ds DNA, anti-ANA DNA and evaluating Hematuria. Baseline Clinical evaluation includes Blood pressure measurement and Kidney structural damage evaluation via biopsy. Then patients will be followed up monthly for three months for assessing Patient Compliance with the prescribed medication regimens and the study drug, Occurrence of side effect graded using monitoring of side effects scale (MOSES) and checking for Allergic reactions against the drug. After the three months, all patients will be reassessed for all laboratory and clinical evaluations. finally results will be statistically analyzed Statistical analysis will be done using SPSS statistical software package

NCT ID: NCT05716035 Recruiting - Clinical trials for Myasthenia Gravis, Generalized

Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis

tMG-E
Start date: April 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the safety and efficacy of tocilizumab in the treatment of generalized myasthenia gravis (gMG) as an extension study for the participants who previously completed Study tMG(NCT05067348).

NCT ID: NCT05718284 Recruiting - Esophageal Cancer Clinical Trials

High Flow Nasal Cannula After Esophagectomy

OSSIGENA1V
Start date: April 1, 2023
Phase: N/A
Study type: Interventional

This study will compare the effect of HFNC versus standard oxygen administration after elective esophagectomy for cancer.

NCT ID: NCT05720078 Recruiting - Clinical trials for Glioblastoma Multiforme, Adult

UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-3 (UNITED-3)

UNITED-3
Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to test whether an adaptive radiation therapy (RT), two-phase approach in participants with glioblastoma impacts local control compared to standard non-adaptive RT approach. The main questions of the study are to see how this adaptive, two-phase RT approach compares to standard RT in terms of: - Local control - Overall and progression-free survival - Patterns of failure - Toxicity, Neurological Function, and Quality of Life

NCT ID: NCT05720273 Recruiting - Clinical trials for Chronic Kidney Disease-Mineral and Bone Disorder

Neutrophil Gelatinase-associated Lipocalin VS Vascular Calcification in Maintenance Hemodialysis Patients

NGAL
Start date: April 1, 2023
Phase: Phase 4
Study type: Interventional

The goal of this observational study or clinical trial is to learn about the effect of neutrophil gelatinase-associated lipocalin (NGAL) on vascular calcification in maintenance hemodialysis patients with secondary hyperparathyroidism (SHPT). The main question it aims to answer is: the predictive effects of blood NGAL level on the efficacy of palicalcitol in the treatment of SHPT and the adverse reactions of vascular calcification progression. Participants will be treated with palicalcitol, followed up and undergo routine series of Chronic Kidney Disease-Mineral and Bone Disorder associated tests before and after treatment.